Merck's antiparasitic drug, Bravecto, received Emergency Use Authorization from the FDA for screwworm infestations in dogs. This expands the drug's approved uses, potentially boosting sales in affected regions during the CDC's emergency declaration.
Merck's Bravecto, already approved for flea and tick prevention, has received Emergency Use Authorization (EUA) from the FDA for new screwworm infestations in dogs. This is a positive development for Merck as it expands the market for an existing product, albeit for a specific, temporary emergency. While not a blockbuster event, it provides an incremental revenue opportunity for Merck's animal health division, Intervet, for the duration of the CDC's emergency declaration. For traders, this represents a minor positive catalyst for MRK, demonstrating regulatory responsiveness and potential for increased product utility in specific health crises.